U.S. markets closed
  • S&P 500

    4,173.85
    +61.35 (+1.49%)
     
  • Dow 30

    34,382.13
    +360.68 (+1.06%)
     
  • Nasdaq

    13,429.98
    +304.99 (+2.32%)
     
  • Russell 2000

    2,224.63
    +53.68 (+2.47%)
     
  • Crude Oil

    65.51
    +1.69 (+2.65%)
     
  • Gold

    1,844.00
    +20.00 (+1.10%)
     
  • Silver

    27.52
    +0.47 (+1.72%)
     
  • EUR/USD

    1.2146
    +0.0062 (+0.51%)
     
  • 10-Yr Bond

    1.6350
    -0.0330 (-1.98%)
     
  • GBP/USD

    1.4102
    +0.0050 (+0.36%)
     
  • USD/JPY

    109.3470
    -0.0870 (-0.08%)
     
  • BTC-USD

    49,683.25
    +202.25 (+0.41%)
     
  • CMC Crypto 200

    1,392.64
    +34.08 (+2.51%)
     
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • Nikkei 225

    28,084.47
    +636.46 (+2.32%)
     

Avid Bioservices: Q3 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Avid Bioservices (NASDAQ:CDMO) increased in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 116.67% over the past year to $0.01, which beat the estimate of ($0.03).

Revenue of $21,806,000 rose by 60.52% year over year, which beat the estimate of $19,070,000.

Looking Ahead

Avid Bioservices Raises Its FY21 Sales From $84M-$88M To $88M-$91m Vs $ 86.26M Estimates

How To Listen To The Conference Call

Date: Mar 08, 2021

Time: 04:30 PM

View more earnings on CDMO

ET Webcast URL: https://edge.media-server.com/mmc/p/i5yaj5yr

Price Action

Company's 52-week high was at $22.13

52-week low: $3.02

Price action over last quarter: Up 58.50%

Company Description

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.